Neuphoria Therapeutics (NEUP) Tax Provisions (2023 - 2026)

Neuphoria Therapeutics (NEUP) has reported Tax Provisions for 4 consecutive years, with -$34793.0 the latest figure, recorded in Q1 2026.

• On a quarterly basis, Tax Provisions rose 57.14% year-over-year to -$34793.0 in Q1 2026; TTM through Mar 2026 was -$370982.0, a 90.83% increase from a year earlier, with the FY2025 full-year figure at -$468366.0, up 87.97% from the prior year.
• Tax Provisions was -$34793.0 for Q1 2026 at Neuphoria Therapeutics, roughly flat from -$34794.0 in the prior quarter.
• Over five years, Tax Provisions peaked at $16383.0 in Q1 2024 and troughed at -$3.8 million in Q2 2024.
• A 4-year average of -$406147.1 and a median of -$34794.0 in 2023 frame the typical range for Tax Provisions.
• Across the five-year window, Tax Provisions jumped 133.36% in 2024 and plunged 595.55% in 2025, its largest moves.
• Over 4 years, Tax Provisions stood at -$34794.0 in 2023, then jumped by 133.36% to $11609.0 in 2024, then tumbled by 399.72% to -$34794.0 in 2025, then increased by 0.0% to -$34793.0 in 2026.
• The last three Tax Provisions figures came in at -$34793.0 (Q1 2026), -$34794.0 (Q4 2025), and -$34793.0 (Q3 2025), per Business Quant data.